Frontlight ResearchEarly access
CompletedNo phase
Liposomal vs Conventional Oral Iron After Sleeve Gastrectomy
Key facts
- Who runs it
- Medeni Şermet
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 70 people enrolled
- Started
- 1 Sept 2025
- Ended
- 31 Jul 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Liposomal Iron
- conventional oral iron
- Record updated
- 3 November 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age between 18 and 65 years
- History of laparoscopic sleeve gastrectomy performed at least 6 months prior to enrollment
- Diagnosis of iron deficiency anemia, defined as:
- Hemoglobin <12 g/dL in women or <13 g/dL in men, and
- Serum ferritin <30 ng/mL or transferrin saturation (TSAT) <20%
- Mild to moderate anemia (hemoglobin ≥9 g/dL)
- Ability to take and swallow oral medications
- Willingness to participate and provide written informed consent Exclusion Criteria
- Active gastrointestinal disease (e.g., inflammatory bowel disease, peptic ulcer disease, or gastrointestinal bleeding)
- Chronic kidney disease with estimated GFR <30 mL/min/1.73 m²
- Use of oral or parenteral iron, vitamin B12, or folate supplementation within the previous 3 months
- Iron overload or hemochromatosis (serum ferritin >300 ng/mL)
- Known allergy or intolerance to iron preparations
- Active malignancy
- Pregnancy or breastfeeding
- Known hemoglobinopathies (e.g., thalassemia, sickle cell disease)
- Blood transfusion within the previous 1 month
- Cognitive or psychiatric disorder interfering with study participation or protocol adherence
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Low-dose liposomal iron (17-34 mg elemental/day) was compared with standard conventional oral iron (100-200mg elemental/day) in the treatment of iron deficiency anemia following sleeve gastrectomy. Liposomal iron provided superior hematological improvement and gastrointestinal tolerance.
The 2 groups in the trial
- Arm 1 Title: Liposomal Iron (Group LD)Treatment being tested
Participants with iron deficiency anemia after laparoscopic sleeve gastrectomy receiving oral liposomal iron.
Treatment: Liposomal Iron
- Arm 2 Title: Conventional Iron (Group KD)Existing treatment, for comparison
Participants with iron deficiency anemia after laparoscopic sleeve gastrectomy receiving conventional oral ferrous iron preparations.
Treatment: conventional oral iron
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Comprehensive Hematological and Biochemical Comparison of Low-Dose Liposomal Iron Versus Standard-Dose Conventional Oral Iron in Iron Deficiency Anemia Following Sleeve Gastrectomy: A Prospective, Randomized Clinical Trial
- Record updated
- 3 November 2026